HopeStage
Back to overview

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Topics
More filters
27277studies shown
Showing 7,165-7,176 of 27,277
Drug study icon
CompletedEUCTR 2008-007457-13

A Randomized, 6-Week, Double-Blind, Placebo-controlled, Fixed-Flexible-Dose, Parallel-Group Study of Lurasidone in the Treatment of Bipolar I Depression

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In Czech Republic
Bipolarity, DepressionHistorical research record
Countries
France, Czechia, Germany
Sponsor
Sunovion Pharmaceuticals, Inc.
Drug study icon
CompletedEUCTR 2008-007482-23

A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In Czech Republic
Bipolarity, DepressionHistorical research record
Countries
France, Czechia, Germany
Sponsor
Sunovion Pharmaceuticals, Inc.
Drug study icon
CompletedEUCTR 2010-019778-34

A RANDOMIZED, 6-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, FLEXIBLE-DOSE, PARALLEL-GROUP STUDY OF LURASIDONE ADJUNCTIVE TO LITHIUM OR DIVALPROEX FOR THE TREATMENT OF BIPOLAR I DEPRESSION IN SUBJECTS ...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In Czech Republic
Bipolarity, DepressionHistorical research record
Countries
Czechia, Lithuania, Slovakia
Sponsor
Sunovion, Inc.
Drug study icon
CompletedNCT00350467

Extended Release(ER) Paliperidone for schizophrenia

Official study title

A Randomized, 6-week Double-blind, Parallel Study to Evaluate the Efficacy and the Safety of Flexible Doses of Extended Release OROS Paliperidone Compared With Olanzapine in the Treatment of Patients With Schizophrenia

This study has finished and is no longer accepting participants.

Multiple locations, including Beijing
SchizophreniaMedication studyAges 18–65
Countries
China
Sponsor
Xian-Janssen Pharmaceutical Ltd.
Device study icon
CompletedNCT06037668

A Controlled Study of Two At-Home Self-Guided Virtual Reality Interventions for Adults With Social Anxiety Disorder.

Official study title

BVR-100 and BES-100 Validation Trial: A Randomized, Double-Blind, Parallel-Group, Controlled Study of Two At-Home Self-Guided Virtual Reality Interventions for Adults With Social Anxiety Disorder.

This study has finished and is no longer accepting participants.

Multiple locations, including Orlando
AnxietyDevice studyAges 18–99
Countries
United States
Sponsor
Sumitomo Pharma America, Inc.
Drug study icon
CompletedEUCTR 2008-001767-11

A Randomized, Controlled, Open-Label Comparison Study of the Efficacy and Safety of Slow Transitioning compared with Fast Transitioning from a Stimulant Medication to Atomoxetine in Pediatric and A...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In Portugal
ADHDHistorical research record
Countries
United Kingdom, Portugal, Spain
Sponsor
Eli Lilly and Company Limited
Drug study icon
CompletedEUCTR 2005-001845-40

A Randomized, Crossover Study to Evaluate the Overall Safety and Tolerability of Paliperidone Palmitate Injected in the Deltoid or Gluteus Muscle in Subjects With Schizophrenia

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In Czech Republic
SchizophreniaHistorical research record
Countries
Czechia, Germany, Slovakia
Sponsor
Janssen-Cilag International N.V.
Drug study icon
CompletedEUCTR 2013-000426-62

A randomized, double blind, placebo-controlled crossover study to investigate the effects of a selective serotonergic reuptake inhibitor on resting state fMRI in healthy volunteers.

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In Netherlands
Anxiety, DepressionHistorical research record
Countries
Netherlands
Sponsor
Centre for Human Drug Research

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.